Awakening to New Drugs Against Sleeping Sickness, University of Mainz and ETH Zurich Study
5/17/2013 7:25:42 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Sleeping sickness kills tens of thousands of people in Africa each year. Current chemotherapies are subject to various limitations, including resistance. Rhodesain, an enzyme of the parasites that cause this illness (human African trypanosomiasis), has emerged as a target for new drug candidates. Scientists led by F. Diederich (ETH Zürich) studied the molecular recognition properties of rhodesain and developed a series of triazine nitrile inhibitors as lead compounds using structure-based molecular modeling.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by